Gelonghui, May 20 | Wanbang Pharmaceutical (301520.SZ) said on the investor interactive platform that the company has not yet carried out drug research and development work on the KP.2 variant.
万邦医药(301520.SZ)：公司暂未开展针对KP.2变异株的药物研发工作
Wanbang Pharmaceutical (301520.SZ): The company has not yet carried out drug research and development work for the KP.2 variant
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.